C. difficile 위험도


Complicated intraabdominal infectionComplicated SSTICAPComplicated UTIPelvic infection1 g IV q24h x5-14d1 g IV q24h x7-14d1 g IV q24h x10-14d1 g IV q24h x10-14d1 g IV q24h x3-10d

Safety and efficacy in pediatric patients <3 months of age have not been established- Age 3m-12y 15 mg/kg IV q12h (max 1 g/d)

  • Age ≥13 y 1 g IV q24h

No dose adjustment

CrCl >30CrCl ≤30HDCRRTNo dose adjustment500 mg IV q24h administered within 6h before HD, additional 150 mg IV after HD500 mg q24h (+150 mg AD if given within 6h prior to HD) OR 500 mg 3x/week AD500-1,000 mg q24h

General Information

Targeted therapy of ESBL infections and other resistant gram-negative infections.

Empiric therapy when broad spectrum of carbapenems is desired without the need for anti-pseudomonal activity.

Monitor hematopoietic, renal, and hepatic function; periodically for patients with prolonged therapy.


  • Abdominal pain

  • Constipation

  • Diarrhea

  • Nausea

  • Vomiting

  • Headache

  • Vaginitis

  • Neutrophil count abnormal


  • Seizure

  • Valproic acid - may decrease valproate levels and may decrease seizure threshold

  • Cholera vaccine, live

  • Tacrolimus

  • Probenecid

Antimicrobial class: Carbapenem

Pregnancy category: B

Average serum half life: 4 hours

Biliary penetration: Moderate

Lung penetration: Therapeutic

Urine penetration: Therapeutic


  • Use caution in patients with history of hypersensitivity to beta-lactam antibiotics and multiple allergens.

  • Not recommended in pediatric patients with meningitis due to lack of sufficient cerebrospinal fluid penetration.

  • Reduce dose or discontinue in patients with seizures or CNS adverse effects.

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.